Collaborative research presents special problems for patent seekers

Article Abstract:

A lot of research is going on in the fields of biotechnology and pharmaceutical companies in collaboration with the universities or private or public organizations. The problems that arise in this collaborative research are that patent applications may be filed for new inventions made, but in this research process later on if someone else invents this and files the application for patent then the examiner has to compare both the results and check whether they satisfy the rules of patentability.

United States, Methods, Action research, Pharmaceutical biotechnology

---

Vox populi and public policy: why should we care?

Article Abstract:

The purpose of a policy on biotechnology should not be to translate the vox populi into policy on subjects dependent on the subtleties of science and technology. Non-experts are becoming more prominent in formulating public policy decisions.

United Kingdom, Product standards, safety, & recalls, Management dynamics, Standards, Management, Biotechnology industry, Biotechnology industries, Technology application, Company business management, Public policy (Law)

---

Where did the BLOSUM62 alignment score matrix come from?

Article Abstract:

Many sequence alignment programs use the BLOSUM62 score matrix to score pairs of aligned residues. Some details in BLOSUM62 that may seem counterintuitive at first glance are explained.

Analysis, Matrix mechanics

Similar abstracts:

• Abstracts: Charitable contributions: special deductions available to corporations
• Abstracts: FERC reexamines treatment of income taxes as recoverable costs for flow-through entities
• Abstracts: Ireland launches regenerative medicine research center. China steps up US biotech intellectual property land grab
• Abstracts: Throwing money at biodefense: US funding for biodefense research continues on an upward trend, but some say the effort is misguided
• Abstracts: Politics torpedo biotech as EU priority. Taiwan: biotech vision. Germany biotech gets second chance

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.